7 news items
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
Cocoon®) and a proprietary quality control testing and release strategy. About GalapagosWe
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
(using Lonza's Cocoon®) and a proprietary quality control testing and release strategy.About GalapagosWe are a biotechnology
Galapagos And Blood Centers Of America Collaborate To Expand Galapagos' Decentralized CAR-T Manufacturing Network In The U.S.
GLPG
15 May 24
strategy, supporting upcoming pivotal trials and potential future commercial manufacturing of CAR-T therapiesComplements
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
GLPG
15 May 24
Important milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future commercial
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
to evaluate business development opportunities that fit our strategy to accelerate and expand our pipeline of potential best-in-class investigational
90fbrvttbtn77z25fig5g
GLPG
4 Apr 24
testing and release strategy. About the ATALANTA-1 study (EudraCT 2021-003272-13)ATALANTA-1
rvggt7ysc04ass3zwazg qo5pfrizjbeto2td0ayy0rzxo8fj9xenr1yr
GLPG
26 Mar 24
corporate development and strategy group. Before joining Gilead, Mr. Dickinson worked at Lazard as global co-head of the healthcare investment banking
- Prev
- 1
- Next